Cite
Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
MLA
Askari, Sanaz, et al. “Memantine Augmentation of Sertraline in the Treatment of Symptoms and Executive Function among Patients with Obsessive-Compulsive Disorder: A Double-Blind Placebo-Controlled, Randomized Clinical Trial.” BMC Psychiatry, vol. 22, no. 1, Jan. 2022, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s12888-021-03642-z.
APA
Askari, S., Mokhtari, S., Shariat, S. V., Shariati, B., Yarahmadi, M., & Shalbafan, M. (2022). Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. BMC Psychiatry, 22(1), 1–13. https://doi.org/10.1186/s12888-021-03642-z
Chicago
Askari, Sanaz, Saba Mokhtari, Seyed Vahid Shariat, Behnam Shariati, Masoomeh Yarahmadi, and Mohammadreza Shalbafan. 2022. “Memantine Augmentation of Sertraline in the Treatment of Symptoms and Executive Function among Patients with Obsessive-Compulsive Disorder: A Double-Blind Placebo-Controlled, Randomized Clinical Trial.” BMC Psychiatry 22 (1): 1–13. doi:10.1186/s12888-021-03642-z.